Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Apr 13, 2020 12:49pm

314 Views

Post# 30903541

RE:Probability of Buy-out by Quarter after Positive 2b Results

If Bayer is not the bigger pharma in the data room sniffing around, they could present an even sweeter hostile big for shareholders.....$6-8 / share

mstrmnd wrote:
Within the next 30-days ATE.V may have proof of concept of the market potential of their API - ATB-346 alone or the entire Hydrogen-Sulfide Therapeutics Platform (net Citagenix).

What's the probability of an M & A with a Big Pharma player over the next:
1. 90-days
2. 180-days
3. 365-days

?

How closely is Bayer following ATE.V? This will be a huge loss for Bayer if they do not act quickly. In the hands of a competitor, Bayer has the most to lose. Is GUD a buyer, a facilitator or neither? Mugs you seem to be the leader of the pack, have shareholders done their part to get ATE.V in the face of Bayer and Big Pharma - even on social media?